China biotechnology Report Interpretation

Overview

This conference wrap examines how global healthcare-company updates create clinical and competitive read-throughs for China biotechnology names. Morgan Stanley focuses on upcoming data catalysts and the efficacy, safety, dosing and treatment-burden benchmarks that could determine differentiation across several therapeutic areas.

Core views

In atopic dermatitis (AD), Morgan Stanley sees systemic penetration of 5–10% as constrained by injection burden and boxed-warning oral therapies. The report argues that expansion could come from cleaner oral options, including STAT6 approaches, and next-generation bispecifics that deliver deeper EASI-90/100 responses. For InnoCare, Keymed, Akeso and Innovent, YE26 STAT6 and ICP-332 data will test whether oral conversion is achievable; bispecific programs will need to demonstrate response depth and durable dosing. Related catalysts include Kymera’s KT-621 BROADEN 2 Phase 2b AD topline at YE26 and detailed ICP-332 Phase 3 AD data plus 52-week safety and an NDA for InnoCare at YE26/early 2027. In ophthalmology, the report describes lifetime wet AMD treatment as still evolving among durable injectables and continuous TKIs, with disease control, monitoring demands and practice economics all relevant. Morgan Stanley highlights retinal structure and BCVA as potential differentiators for assets spanning atrophy and VEGF pathways. Innovent’s IBI302, targeting VEGF/complement coverage, could address both axes, while IBI324’s differentiation is to be tested through BCVA and treatment load in global Phase 3. The catalyst table points to EyePoint’s LUCIA Phase 3 wet-AMD BCVA result in 4Q26 as a read-through for IBI302 and IBI324. For achondroplasia (ACH), low US penetration is viewed as supportive of new-start oral uptake, whereas higher European penetration favors switching. Morgan Stanley notes that infant and toddler development before PROPEL 3 could increase regulatory comfort with infigratinib’s toxicity profile. BBIO’s infigratinib label is expected to set benchmarks for height, function and pediatric safety, while Abbisko’s ABSK061 Phase 2 will test untreated and CNP-exposed patients at YE26; preliminary efficacy and safety data are listed for 4Q26. In Alzheimer’s disease, established therapies are expanding blood-based diagnosis, subcutaneous delivery, ARIA-management capacity and earlier-stage studies. Against that backdrop, Keymed and Akeso programs face higher standards for brain exposure, earlier treatment use, subcutaneous delivery and ARIA management. Morgan Stanley notes that BBB platforms are seeking lower systemic exposure and multi-target treatment; Denali’s tau biomarker data and Aβ safety/clinical proof-of-concept updates in 1H27/2027 are identified as relevant read-throughs. For small-cell lung cancer, Morgan Stanley says DeLLphi-305 and shorter FDA monitoring support earlier-line tarlatamab use and broader adoption in community settings. Zai Lab’s zoci first-line SCLC data at ESMO in October 2026 is expected to clarify its potential in earlier-line combinations with tarlatamab. The report also flags Amgen’s full DeLLphi-305 first-line-maintenance dataset and regulatory engagement as a near-term catalyst.

Analysis framework

Morgan Stanley uses conference discussions and company-disclosed catalyst timelines to identify therapeutic-area benchmarks, then links global clinical readouts to potential differentiation and read-throughs for China biotech programs. The analysis compares efficacy depth, durability, safety, delivery route, monitoring burden and regulatory requirements across competing approaches.

Methodology notes

• Event-Driven and Behavioral FinanceEvent-driven analysis

  Clinical-catalyst and cross-read analysis

  The report maps scheduled trial, regulatory and conference events to the China biotech assets whose competitive positioning could be clarified by those outcomes.

• Industry AnalysisSubstitution-Effect Analysis

  Treatment-modality competition

  The report compares oral, injectable, subcutaneous, BBB-platform and other treatment approaches to explain where lower burden, improved exposure or stronger outcomes may shift treatment adoption.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• InnoCare

  AD and psoriasis catalyst exposure through ICP-332 and ICP-488

  Strengths

  ICP-332 data may test oral conversion in AD.

  Weaknesses

  Differentiation depends on clinical data and longer-term safety.

  Comparison

  Competes with clean oral STAT6 approaches and next-generation bispecifics on AD outcomes.

  Risks

  YE26 and early-2027 clinical, safety and regulatory outcomes may not meet the required differentiation threshold.

• Innovent

  Ophthalmology exposure through IBI302 and IBI324

  Strengths

  IBI302 could provide coverage across atrophy and VEGF axes.

  Weaknesses

  IBI324 differentiation remains to be validated.

  Comparison

  Competes in a wet-AMD setting balancing durability, monitoring and practice economics.

  Risks

  BCVA and treatment-load evidence in global Phase 3 may not support differentiation.

• Abbisko

  ACH exposure through ABSK061

  Strengths

  The program will test untreated and CNP-exposed patients.

  Weaknesses

  It must meet height, function and pediatric safety standards shaped by infigratinib.

  Comparison

  BBIO’s infigratinib label is the cited benchmark.

  Risks

  Phase 2 efficacy and safety data may not clear emerging regulatory and competitive bars.

• Keymed and Akeso

  Exposure to AD bispecific and Alzheimer’s therapeutic competition

  Strengths

  Programs participate in areas where deeper responses, brain exposure and delivery innovation could matter.

  Weaknesses

  They face rising requirements for CNS exposure, earlier treatment, subcutaneous delivery and ARIA management.

  Comparison

  Benchmarked against incumbent and next-generation peers.

  Risks

  Programs may not demonstrate adequate differentiation on efficacy, delivery or safety management.

• Zai Lab

  First-line SCLC combination-development exposure through zoci

  Strengths

  Upcoming first-line data may clarify combination potential with tarlatamab.

  Weaknesses

  Earlier-line positioning remains dependent on clinical evidence.

  Comparison

  Read through against DeLLphi-305 and evolving tarlatamab use.

  Risks

  ESMO first-line SCLC data may not support the intended earlier-line combination opportunity.

Key data

• Systemic penetration in AD5–10%Morgan Stanley states that injection burden and boxed-warning orals currently constrain penetration.
• Zoci first-line SCLC dataOctober 2026ESMO catalyst for assessing earlier-line combination potential.
• ABSK061 Phase 2 preliminary data4Q26Expected efficacy and safety update in ACH.
• ICP-332 detailed Phase 3 AD data and 52-week safety/NDAYE26/early 2027Key InnoCare catalyst for the AD oral-conversion thesis.
• EyePoint LUCIA Phase 3 wet-AMD BCVA result4Q26A read-through for ophthalmology assets IBI302 and IBI324.

Impact & implications

The report indicates that upcoming clinical and regulatory events will be important for establishing whether China biotech programs can differentiate on efficacy, durability, safety, delivery convenience and monitoring requirements. Global readouts may set the competitive bars against which the identified China assets are judged.

Risks

• Clinical data may fail to meet the efficacy, durability, safety or treatment-burden benchmarks identified by the report.
• Regulatory outcomes and competitive labels may raise the standards required for China biotech programs to differentiate.

What to watch

• YE26 STAT6 and ICP-332 data in AD, including ICP-332 Phase 3 details and 52-week safety.
• Zoci first-line SCLC data at ESMO in October 2026 and Amgen’s DeLLphi-305 follow-up.
• IBI324 global Phase 3 BCVA and treatment-load evidence, alongside relevant wet-AMD readouts.
• ABSK061 Phase 2 ACH efficacy and safety data in 4Q26.
• Alzheimer’s advances in blood-based diagnosis, subcutaneous delivery, ARIA capacity and BBB-platform development.